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As a Mendelian neurodegenerative disorder, the ge-
netic risk of Huntington’s disease (HD) is conferred
entirely by an HTT CAG repeat expansion whose
length is the primary determinant of the rate of path-
ogenesis leading to disease onset. To investigate the
pathogenic process that precedes disease, we used
genome-wide association (GWA) analysis to identify
loci harboring genetic variations that alter the age
at neurological onset of HD. A chromosome 15 locus
displays two independent effects that accelerate
or delay onset by 6.1 years and 1.4 years, respec-
tively, whereas a chromosome 8 locus hastens onset
by 1.6 years. Association atMLH1 and pathway anal-
ysis of the full GWA results support a role for DNA
handling and repair mechanisms in altering the
course of HD. Our findings demonstrate that HD dis-
ease modification in humans occurs in nature and
offer a genetic route to identifying in-human vali-
dated therapeutic targets in this and other Mendelian
disorders.
INTRODUCTION
For the past three decades, a major goal of genetic analysis in
humans has been to understand drivers of disease pathogenesis
with the hope that these would implicate targets for developing
therapeutic interventions. Initially, the primary approaches
were linkage analysis and local association, often using multi-
allelic simple sequence repeat markers, which enabled the iden-
tification of a wide range of causative Mendelian mutations,
including that underlying Huntington’s disease (HD) (The Hun-
tington’s Disease Collaborative Research Group, 1993). For
the past decade, genome-wide association (GWA) analysis
with SNPs has extended the power of human genetic studies
to complex diseases by identifying a multitude of contributing
risk factors, usually of modest or weak effect (Manolio et al.,
2009). In this report, aided by visionary HD community efforts
to collect phenotypes and biosamples from large numbers of
subjects with this disorder (Dorsey, 2012; Li et al., 2003; Orth
et al., 2010; Paulsen et al., 2008), we apply GWA not to identify
risk factors for disease but to discover genome-wide significant
quantitative modifiers of a Mendelian disorder.
In HD, a CAG trinucleotide expansion mutation in HTT, the
gene encoding the large huntingtin protein, causes a progressive516 Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc.movement disorder with dementia and behavioral abnormalities
(Ross et al., 2014). Unequivocal clinical signs of HD typically
emerge in mid-life, but juvenile onset and elderly onset cases
are seen. Diagnosis is based upon the presence of characteristic
motor signs, but the disorder includes intellectual decline and
psychiatric disturbances, with death ensuing a median of 18
years after onset. The expanded CAG tract is the trigger for HD
pathogenesis, and its length is the primary determinant of the
rate of the pathogenic process that leads to the onset of diag-
nostic motor signs (referred to here for simplicity as ‘‘motor
onset,’’ although more subtle signs may be present before clin-
ical diagnosis) (Lee et al., 2012b). For individuals with 40 or
more CAG repeats, the expansion is necessary and sufficient
to cause HD, accounting for essentially all of the life-time risk
of developing the disorder. Although symptomatic treatment
can improve quality of life, there is no disease-modifying inter-
vention to prevent the onset or delay the progression of HD.
Because targets validated to impact on the disease process in
humans have been lacking for traditional small-molecule ap-
proaches to drug development, a current focus for developing
an effective disease-modifying therapy is the exploration of cut-
ting-edge nucleic acid manipulation to prevent expression of
mutant huntingtin (Aronin and DiFiglia, 2014). However, such
strategies remain unproven in humans and pose numerous hur-
dles, including achieving efficient delivery and avoiding the po-
tential negative effects of reducing normal huntingtin function.
Thus, an effective route for identification of in-human validated
therapeutic targets for traditional drug development is also
needed.
Here, we postulated that the presence of the expandedCAG in
an individual provides a genetically sensitized background on
which to search not for risk alleles but for genetic modifiers of
the disease process, which may be common in the population
but not have detectable effects in the absence of the HD muta-
tion. Consequently, we applied a GWA strategy to quantitative
variations in the disease phenotype in an unbiased search for
naturally occurring genetic variations associated with modifica-
tion of HD pathogenesis prior to emergence of clinical disease.
Our findings localize several genome-wide significant genetic
modifiers of HD age at onset and already suggest at least one
biochemical process that alters HD pathogenesis in humans
and can be specifically targeted for traditional drug develop-
ment. The approach of separating disease risk and disease
modification in a Mendelian disorder, merged with the power
of modern genetic techniques, is widely applicable and has the
potential to implicate new therapeutic pathways in human dis-
eases that are individually not common but that taken together
constitute a substantial disease burden.
Definition of the Phenotype for Association Analysis
Within a year after the identification of the HD mutation, the in-
verse relationship between CAG length and age at diagnostic
motor onset, which lays the foundation for a genetics-driven
approach to understanding HD, was recognized (Gusella and
MacDonald, 2006). This relationship establishes that the size of
the mutant repeat is the primary determinant of the rate of path-
ogenesis leading to the emergence of clinical signs of disease
(Lee et al., 2012b). The length of the expanded CAG repeat ex-
plains much, but not all, of the variation in age at motor onset.
We and others have reported that the remaining variance has a
large heritable component, implicating the actions of other ge-
netic variations in modifying HD pathogenesis and suggesting
that the difference between predicted and observed age of onset
could be used in genetic studies to identify modifiers (Djousse´
et al., 2003; Wexler et al., 2004). Haplotype analysis of HTT in
HD subjects indicates that common genetic variation at the locus
is not a major source of disease modification (Lee et al., 2012a),
and the length of the normal CAG repeat in heterozygotes shows
no statistically significant modifier influence, either alone or in
interaction with the expanded allele (Lee et al., 2012b). Indeed,
there is also no effect of a second expanded CAG allele on age
at onset, indicating that HD pathogenesis is not HTT dosage
dependent but rather reflects the completely dominant effects
of a single mutant allele. These stringent analyses generated a
robust statistical phenotype model, based upon subjects with
40–53 CAG repeats (Figure S1), which was used to calculate
the influence of the CAG repeat on log-transformed age at onset
of motor signs of HD subjects in the GWA study (GWAS), thereby
generating a residual value for each subject. Residual values
from the regression model were transformed back into natural
scale values as a phenotype for quantitative association analysis
to search the genome for genetic variation that influences age at
motor onset. The distribution of residuals was similar to a theo-
retical normal distribution. This ‘‘residual age at motor onset’’
used as the GWA phenotype thus represents the difference in
years between observed age at onset and that expected based
upon the individual’s CAG repeat size. We analyzed individuals
with 40–55 repeats; however, restricting analysis to individuals
with 40–53 repeats did not materially alter our results.
Initial Genome-wide Association Studies
Over almost three decades of investigating HD, the Massachu-
setts HD Center Without Walls (MaHDC) accumulated a
large collection of DNA samples from HD subjects, including
collaborations with the HSG PHAROS (Huntington Study
Group PHAROS Investigators, 2006), COHORT (Dorsey, 2012),
TREND-HD (Huntington Study Group TREND-HD Investigators,
2008), and PREDICT-HD (Paulsen et al., 2008) studies, and
from families for linkage and other genetic studies, including a
sib-pair linkage scan for modifiers of HD onset with the HD-
MAPS collaboration (Li et al., 2003). This collection formed the
basis for a collaborative effort that led to generation of two
sequential GWA datasets. For the initial dataset (GWA1), 1,089
HD subjects were genotyped with the Affymetrix 6.0 array at
the Broad Institute of MIT and Harvard. Data cleaning was car-
ried out using standard quality-control criteria (e.g., SNP call
rate > 95%,minor allele frequency [MAF] > 1%, Hardy-Weinbergequilibrium p value > 1 3 106, sample call rate > 95%). After
quality-control analysis, multidimensional scaling analysis re-
vealed 977 unique subjects of European ancestry with CAG
repeat lengths in the range 40–55. Analysis of GWA1 (after
QC: 700,000 typed and 8 million 1000 Genomes-imputed
SNPs with MAF > 1%) did not reveal any genome-wide signifi-
cant signals for association with the phenotype of ‘‘residual of
age at motor onset’’ in a linear mixed model with covariates
including ancestry characteristics and gender (see Experimental
Procedures for details). GWA1 provided the basis for building
SNP haplotypes of HTT that revealed that 50% of European
HD subjects share a haplotype indicative of a common ancestor,
but the rest are consistent with mutation on multiple other chro-
mosome backbones contributing to HD (Lee et al., 2012a). No
effect of HTT haplotype on the age at onset phenotype was de-
tected, permitting all HD subjects to be grouped for our GWA
analyses.
In a second phase of genotyping (GWA2), additional subjects
from the MaHDC collection were combined with subjects from
the PREDICT-HD natural history study. GWA2 involved 2,874
HD subjects genotyped using the Illumina Omni2.5 array at the
Center for Inherited Disease Research (CIDR). Age at onset
was known for only a subset of these subjects, mainly those
from the MaHDC, as PREDICT-HD enrolled subjects prior to
manifestations of diagnostic clinical signs. Data quality-control
analysis was similar to GWA1 and yielded 974 unique individuals
of European ancestry suitable for our association analysis. Full
genotyping data and associated phenotypes for GWA2 have
already been deposited into dbGAP, including an extensive
and detailed description of the data cleaning steps. Like
GWA1,GWA2 (after QC:1.5million genotyped and8.6million
1000 Genomes-imputed SNPs with MAF > 1%) failed to identify
a genome-wide significant signal for association to residual age
at motor onset. However, a combined analysis of GWA1+GWA2,
which increased the effective sample size to 1,951 unique Euro-
pean HD subjects, revealed a genome-wide significant signal,
represented by two SNPs on chromosome 15 (chr15) (best
SNP, p = 4.36 3 109; rs146353869) (Figure 1A).
Follow-up Genome-wide Association Study
To confirm the genome-wide significant signal on chr15 in an in-
dependent dataset and to implicate new loci through the
increased power of a larger combined analysis, we formed the
Genetic Modifiers of HD (GeM-HD) Group to carry out GWA3.
Genotyping was performed at the Broad Institute using the Illu-
mina Omni2.5 array for 3,447 HD subject samples from the
MaHDC collection and from the European Huntington’s Disease
Network (EHDN) Registry study (Orth et al., 2010). After QC,
GWA3 comprised 2,131 unique individuals of European ancestry
suitable for our analysis of association to the residual age at
motor onset. GWA3 alone independently confirmed the chr15 lo-
cus at a genome-wide significance level (best SNP, p = 1.35 3
1012; rs146353869).
Meta-analysis of the two linear mixed-effect model results
(combined GWA1+GWA2 and GWA3; n = 4,082) improved the
significance of the best SNP on chr15 to p = 4.3 3 1020 and
also yielded a second genome-wide significant locus on chr8
(p = 2.7 3 108, rs1037699) with suggestive trails at otherCell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc. 517
Figure 1. Genome-wide Association Anal-
ysis of Residual Age at Motor Onset
(A) Manhattan plot of combined GWA1+GWA2
analysis yielding a locus with genome-wide
significance on chr15. GWA1 and GWA2 data
were combined and tested for association with
residual age at onset. Significance of SNPs
(log10[p value], y axis) is plotted against genomic
location (x axis). The QQ plot (Figure S1C) did not
reveal significant statistical inflation evidenced by
an inflation factor of 1.014.
(B) Manhattan plot of meta-analysis of GWA1+2
and 3 showing genome-wide significant peaks at
chr15 and chr8 and near-significant on chr3, along
with other trails. Association analysis was initially
performed independently on GWA3 data (not
shown), and then a meta-analysis was performed
to summarize theoverall association findingsof the
GWA1+GWA2 and GWA3 analyses. The overall
inflation factor of 1.009 suggests the absence of
statistical inflation in this analysis (Figure S1D).
The red dotted lines in (A) and (B) indicate the
genome-wide significance level (p value, 53 108).
The GeM-HD Group has developed a web portal
through which interested investigators can access
the genome-wide SNP association data by SNP,
gene, or genomic location of interest. This can be
accessed through the HDinHD portal (https://
www.hdinhd.org/). Original data will be made
available on request. Please direct inquiries to
info@chdifoundation.org with the words ‘‘GWAS
data’’ in the subject line.
See also Figure S1 and Table S1.locations, such as chr3, chr5, and chr21 (Figure 1B). The
most significant variants at all locations that achieved a peak
p < 1 3 106 are given in Table 1, whereas a more extensive
list of all SNPs yielding p < 13 105 is presented in Table S1.
To test the robustness of the quantitative association analysis
to outliers with large residuals of age at onset, we also performed
a dichotomous analysis. Individuals whose phenotypes fell into
the 20% extremes of either earlier or later than expected age
at onset were compared formarker allele frequency in a standard
‘‘case:control’’ GWAS design. Logistic regression analysis with
ancestry characteristics and gender covariates was imple-
mented using the combined datasets. Results from the
genome-wide dichotomous analysis are shown in Figure 2, and
details of allele frequency are also provided (in Table S2) for
the top SNPs from quantitative analysis. Even though the dichot-
omous comparison comprised only 40% of the samples, the
chr15 region again showed genome-wide significance (best
SNP, p = 7.9 3 1015; rs2140734), and the same secondary
peaks on other chromosomes were readily discernible. Thus,
detection of these loci does not depend critically on the precise
magnitude of the residual of age at onset in the quantitative anal-
ysis, as the shift of individuals toward one or the other tail of the
distribution creates contrasting allele frequencies between these
extremes.
Conditional Analysis and Effect Size
To determine whether any of the top loci show evidence of more
than one functional modifier allele, we carried out conditional as-518 Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc.sociation analysis using a fixed-effect model of the combined
data as shown in Figure 3A for the chr15 region. The bottom
panel shows an expanded view of the chr15 locus association
plot. When a fixed-effect model was conditioned by the most
significant SNP (rs146353869, red circle), many of the most sig-
nificant signals disappeared (Figure 3A, top panel), but a large
number of SNPs remained above the genome-wide significant
level (red dotted line, best SNP = rs2140734, green circle), indi-
cating a second modifier effect independent of that captured by
rs146353869. This was confirmed by conditioning the analysis
on rs2140734 (Figure 3A, middle panel), whose characteristics
are also listed in Table 1. Interestingly, the minor alleles for
SNPs detecting these two independent signals are associated
with opposing effects. The SNPs with the most significant
p values all show a relatively low MAF (1.3%–3.0%), and each
minor allele corresponds with up to 6.1 years earlier age at onset
than expected based upon CAG length (range 2.9 to 6.1
years/minor allele for 34 SNPs). To avoid any contribution of a
‘‘winner’s curse,’’ we also estimated the effect size in only the
GWA3 dataset accumulated after genome-wide significance
had already been achieved. In this independent confirmation da-
taset, the effect size for rs146353869 was 6.2 years/minor
allele (in a mixed-effect model). The genome-wide significant
SNPs at the chr15 locus that detect the second, independent as-
sociation signal all display a much higher MAF (27.0%–39.1%)
and are associated with a delay in motor onset of up to 1.4 years
(rs2140734; range +1.1 to 1.4 for 91 SNPs; +1.4 years/minor
allele for rs2140734 in GWA3 alone by mixed-effect model
Table 1. Most Significant Variants Associated with Residual Age at HD Motor Onset
SNP Chr BP (hg19) Minor Allele Major Allele
MAF in
Europeans (%)b
MAF in European
HD (%)
Effect Size (Years/
Minor Allele)
p Value in meta
Analysisa
rs147804330 2 56391203 A G 8.0 6.3 1.6 7.6 3 107
rs72810940 2 75555265 A G 3.4 2.9 2.4 5.9 3 107
rs144287831 3 37068079 C T 32.5 31.2 0.9 2.2 3 107
rs11133929 5 2155168 C T 9.4 9.3 1.5 2.1 3 107
rs1037699 8 103250930 T C 8.3 9.6 1.6 2.7 3 108
rs11061229 12 131389783 C G 6.9 6.6 1.7 6.7 3 107
rs261453 13 82324504 A C 9.9 11.4 1.3 9.0 3 107
rs148491145 14 72360176-72360182 — GACTCTA 2.0 1.5 3.2 7.5 3 107
rs146353869 15 31126401 A C 1.1 1.7 6.1 4.3 3 1020
rs2140734 15 31243792 G T 30.2 30.4 1.4 7.1 3 1014
rs143367341 21 28348433 G A 14.6 13.5 1.3 2.5 3 107
See also Table S1.
aThe most significant variant is shown for each independent signal with p < 1 3 106. Genome-wide significant signals are shown in bold. See also
Table S1.
bMAF (%) in Europeans represents the minor allele frequency in 1000 Genomes project data phase 3, except rs143367341 (1000 Genomes Project
data, phase 1, release3).analysis). These two independent modifier effects reflect the
presence in the population, on different versions of chr15, of
two separate functional variants that likely have opposing im-
pacts on the same gene. Unlike the chr15 region, the other loci
listed in Table 1 each suggest only a single modifier allele. Exam-
ples are shown in Figures 3B and 3C for chr8 and chr3, where
conditioning the analysis on the respective top SNPs
(rs1037699 and rs144287831) dramatically reduced other asso-
ciation signals in the corresponding region. We did not detect
any significant interaction between the four independent
SNPs representing chr15 (rs146353869 and rs2140734), chr8
(rs1037699), and chr3 (rs144287831) in pairwise tests. Further-
more, models directly testing interaction between each SNP
and HTT CAG repeat length did not support the significance of
CAG:SNP interaction term, suggesting independent effects
acting equally across the range of expanded repeats.
Genes near Top Association Signals
As with any GWA analysis, the location of the significant SNPs
does not immediately identify which gene mediates the conse-
quences of the as yet unknown functional variant, but several
candidates are evident for the genome-wide significant loci. At
the chr15 locus, a recombination frequency peak (cyan line
in Figure 3A) on the telomeric side coincides with the loss of
both independent significant association signals, which extend
proximally in a region containing the two highest priority candi-
date genes, MTMR10 (myotubularin related protein 10) and
FAN1 (Fanconi anemia FANC1/FANCD2-associated [endo]
nuclease 1), alongwith the pseudogeneHERC2P10 in a segment
that also specifies several putative large intergenic non-coding
RNAs (lincRNAs). On chr8 (Figure 3B), the significant association
signal also extends across two high-priority candidate genes,
RRM2B (a subunit of DNA damage p53-inducible ribonucleotide
reductase M2 B) and UBR5 (an HECT domain E3 ubiquitin-pro-
tein ligase). The region also contains the microRNA gene
MIR5680 and the 50 end of NCALD (neurocalcin delta). Amongthe top loci that did not reach genome-wide significance, the
most notable is that on chr3 (Figure 3C), which centers on
MLH1 (the human homolog of the E. coli DNA mismatch repair
gene mutL), whose mouse homolog, Mlh1, was discovered in a
genome-wide genetic screen to modify somatic instability of
the CAG repeat and the timing of CAG length-dependent pheno-
types in the striatum of genetic HD replica CAG knockin mice
(Pinto et al., 2013).
Pathway Analysis
To examine systematically whether variants associated with
altered age at onset, extending beyond the most significant
hits, cluster in genes with common biological function, we per-
formed pathway analyses using three approaches chosen to
have different characteristics: Setscreen, ALIGATOR, and
gene-set enrichment analysis (GSEA). Setscreen (Moskvina
et al., 2011) combines p values from all SNPs in a pathway, mak-
ing it advantageous for genes and pathways containing multiple
quasi-independent signals of modest size. However, this
approach may lose power when the pathways contain a few
strong signals with many SNPs showing no association.
ALIGATOR (Holmans et al., 2009) defines genes as ‘‘significant’’
based on theirmost significant SNP and tests whether a pathway
contains a higher number of significant genes than would be ex-
pected by chance, taking into account gene size and linkage
disequilibrium between genes. This gives good power to detect
pathways in which there is one strong association signal per
gene but has the disadvantage of requiring that a criterion be
set for defining significant SNPs and genes. GSEA (Wang
et al., 2007) ranks genes in order of a gene-wise significance
measure, then tests whether pathway genes have a significantly
high rank, weighting by the significance measure. For each anal-
ysis, we conservatively assigned SNPs between the start of the
first and the end of the last exon of any transcript to the corre-
sponding gene. To avoid making a priori assumptions about
the areas of biology involved in the modification of age at motorCell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc. 519
Figure 2. Dichotomous Association Anal-
ysis in Extremes of Age at Motor Onset
Association analysis was carried out to compare
SNP allele frequencies between the 20% extremes
of residual age at motor onset, showing that the
modifier effect on chr15 is captured by the allele
frequency distribution in addition to quantitative
analysis.
See also Table S2.onset, we deliberately chose to use a large pathway set covering
as many areas of biology as possible, comprising 14,706 func-
tional gene sets, many with overlapping members, containing
between 3 and 500 genes: 10,741 from GO, 265 from KEGG,
1897 from MGI, 119 from PANTHER, 217 from Biocarta, 1248
from Reactome, and 219 from NCI.
In the primary Setscreen analysis, 14 pathways were signifi-
cant after correcting for multiple testing (q < 0.05). These are
listed in Table 2, together with their enrichment p values under
the ALIGATOR and GSEA analyses. Enrichment p values under
all analysis methods are given in Table S3 for the 326 pathways
with p < 0.05 in the Setscreen analysis. Figure 4 shows that the
14 significant pathways from Table 2 group into three clusters by
gene membership: DNA repair, mitochondrial fission, and oxido-
reductase activity. Pathways in the DNA repair cluster also show
significant enrichment under the ALIGATOR and GSEA analysis
(Table 2), increasing confidence that the enrichments are
genuine. Best SNP and gene-wide p values for the genes in these
clusters are given in Table S4. Gene-wide p values are calculated
using the method of Brown (Brown, 1975), similar to that used in
Setscreen. Note that FAN1 (together with ERCC3) is a member
only of GO:33683 (nucleotide-excision repair, DNA incision),
although it is a member of the broader pathway GO:6281 (DNA
repair), which has nominally significant (p = 0.012) evidence
for enrichment (see Tables S3 and S5). Thus, the significant
enrichments observed in the DNA-repair pathways in Table 2
are achieved independently of the association region on chr15.
If genome-wide significant (p < 5 3 108) SNPs are removed
from the Setscreen analysis, GO:33683 is still significant
(p = 8.653 105), with the other pathways in Table 2 being unal-
tered. Genes with gene-wide p < 0.1 from all 326 pathways
significantly enriched (p < 0.05) in the Setscreen analysis are
shown in Table S5.
Effects on Age at Onset of Cognitive and Psychiatric
Signs
In addition to motor signs, HD subjects also show cognitive dif-
ficulties and sometimes exhibit prominent psychiatric distur-
bance that may precede their movement disorder. The age at
onset for cognitive and psychiatric signs was noted for limited
subsets of our genotyped subjects of European ancestry.
Consequently, we tested the hypothesis that the SNPs showing
genome-wide significant association with residual age at motor
onset also reveal modification of these non-motor phenotypes.
The sample sizes of subjects with CAG 40–55 repeats for these520 Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc.analyses comprised 843 subjects with a recorded age at onset of
cognitive signs and 1,515 with a known age at onset of psychiat-
ric signs, as scored by an expert rater familiar with HD. Each of
these phenotypes shows a negative correlation with CAG repeat
length, explaining 49.3% and 39.2% of the variance in age at
onset, respectively (Figure S2), as compared with 59.4% for
the motor phenotype. Both are very significantly correlated
(Pearson correlation p value < 2.23 1016) with age at motor
onset (Pearson correlation coefficients of 0.891 and 0.804,
respectively), but we sought to assess whether differential ef-
fects might be revealed by the actions of the modifier loci.
Because stringent phenotypemodels describing the relationship
between age at onset of cognitive or psychiatric onsets and CAG
repeat length have not yet been developed, we tested the effects
of the independent significant SNPs associated with residual
age at motor onset by modeling log-transformed age at onset
of cognitive signs or psychiatric signs as a function of CAG
repeat length, SNP, gender, and four ancestry covariate values
in a combined fixed-effect model analysis framework. For com-
parison, we also applied this analytical approach to age at motor
onset, which yielded p values that were only slightly different
than the residual-based analysis above.
For both age at cognitive onset and age at psychiatric onset,
the independent signals at the chr15 locus both showed a nomi-
nally significant association, hastening or delaying cognitive or
psychiatric onset in the same direction as the respective effect
on motor onset (Table 3). The chr8 modifier was also nominally
significant for association with age at cognitive onset and age
at psychiatric onset. Interestingly, although the chr3 locus at
MLH1 showed near-significance for psychiatric onset, there
was no evidence of any effect on cognitive onset, contrasting
with the other modifier loci and suggesting that the different
modifiers may act on different processes to accomplish their ef-
fect on HD pathogenesis. This suggests that not all modifiers of
motor onset influence other HD phenotypes and that future
analyses of larger HD datasets specifically for cognitive and psy-
chiatric phenotypesmay reveal additional modifying genetic var-
iants distinct from those that alter age at motor onset.
DISCUSSION
Investigation of humans with an expanded HTT CAG allele and
studies of model systems in which full-length mutant huntingtin
is expressed, including both human cells and CAG knockin
mice, support the view that the HD mutation has effects
Figure 3. Conditional Association Analysis at Top Loci
(A) Chromosome 15 locus.
Bottom panel: The single SNP association analysis of the combined dataset using a fixed-effect model is shown above the recombination rate (cyan line), based
upon HapMap samples, and the largest transcript for each annotated gene in the region (blue arrows). The red and green circles represent the most significant
independent SNPs that emerged from the conditional analyses shown in the middle and top panels.
Middle panel: Single SNP association analysis conditioned by rs2140734 (green in bottom and top panels) revealing a group of SNPs that remain significant after
removing the effect associated with rs2140734.
Top panel: Single SNP association analysis conditioned by rs146353869 (red in bottom andmiddle panels) revealing a group of SNPs that remain significant after
removing the effect associated with rs146353869.
(B) Chromosome 8 locus.
Bottom panel: The chr8 locus single SNP association analysis of the combined dataset using a fixed-effect model is shown above the recombination rate (cyan
line), based upon HapMap samples, and the largest transcript for each annotated gene in the region (blue arrows). The red circle represents the most significant
SNP that was used in the conditional analysis.
Top panel: Single SNP association analysis conditioned by rs1037699 (red in bottom panel) revealing that all SNPs that showed association in the original as-
sociation analysis were no longer significant after removing the effect associated with rs1037699.
(C) Chromosome 3 locus.
Bottom panel: The chr3 locus single SNP association analysis of the combined dataset using a fixed-effect model is shown above the recombination rate (cyan
line), based upon HapMap samples, and the largest transcript for each annotated gene in the region (blue arrows). The red circle represents the most significant
SNP that was used in the conditional analysis.
Top panel: Single SNP association analysis conditioned by rs144287831 (red in bottom panel) revealing that all SNPs that showed association in the original
association analysis were no longer significant after removing the effect associated with rs144287831.throughout life due to a completely dominant gain-of-function
mechanism that leads after decades to onset of clinical signs
(Gusella et al., 2014). The precise biological differences distin-
guishing individuals who possess expanded CAG alleles and
will develop HD from those with normal-length CAG alleles
whowill not are not well understood. However, the proof-of-prin-
ciple that HD disease modification is possible is demonstrated
not by medical treatment but by observations of a heritableportion of the variance in age at onset that is not explained by
either the size of the CAG repeat or other HTT region polymor-
phisms (Lee et al., 2012a). Instead functional variants exist in
the human population that do not themselves confer risk of HD
but are capable of modifying the course of the disorder during
the long phase that precedes emergence of clinical disease, re-
sulting in earlier or later onset than expected based upon the in-
dividual’s expanded CAG repeat length. In essence nature hasCell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc. 521
Table 2. Pathways Significant after Multiple-Testing Correction (q < 0.05) in the Primary Setscreen Analysis and Enrichment p Values
For ALIGATOR And GSEA
Pathway p(Set-screen) q(Set-screen) p(ALIGATOR) p(GSEA) Description
GO:0090200 8.89 3 108 0.0007 NA 0.1040 positive regulation of cytochrome c release from
mitochondria
GO:0033683 1.69 3 106 0.0063 0.0087 0.0030 nucleotide-excision repair, DNA incision
GO:0090141 2.30 3 106 0.0063 NA 0.1314 positive regulation of mitochondrial fission
GO:0006298 3.25 3 106 0.0066 0.0086 0.0074 mismatch repair
KEGG:3430 6.65 3 106 0.0101 0.0732 0.0280 mismatch repair
GO:0030983 7.43 3 106 0.0101 0.00254 0.0062 mismatched DNA binding
GO:0090140 1.57 3 105 0.0169 NA 0.1560 regulation of mitochondrial fission
GO:0032389 1.66 3 105 0.0169 0.00072 0.0382 MutLalpha complex
GO:0004748 2.66 3 105 0.0217 NA 0.0380 ribonucleoside-diphosphate reductase activity,
thioredoxin disulfide as acceptor
GO:0016728 1.65 3 105 0.0217 NA 0.0380 oxidoreductase activity, acting on CH or CH2 groups,
disulfide as acceptor
GO:0032300 3.82 3 105 0.0283 0.00088 0.0058 mismatch repair complex
GO:0032407 5.74 3 105 0.0390 0.00127 0.0062 MutSalpha complex binding
GO:0010822 7.63 3 105 0.0478 NA 0.0436 positive regulation of mitochondrion organization
GO:1900063 8.39 3 105 0.0488 NA 0.0376 regulation of peroxisome organization
NA means that the pathway contained fewer than two significant genes in the ALIGATOR analysis.
Note that many of these pathways contain overlapping sets of genes, allowing them to be clustered as shown in Figure 4. See also Tables S3,
S4, and S5.achieved disease modification, the goal of those seeking thera-
peutic interventions, and it has remained for investigators to
identify the means by which it occurs. Genetic modifiers could
lead to a better understanding of the genes and processes that
impact on HD pathogenesis and provide in-human validated tar-
gets for traditional small-molecule therapies. The significant loci
that have emerged from our unbiased genome-wide search for
variants associated with altered age at diagnostic motor onset
offer a different entre´e into influencing pathogenesis in this
long-studied but still intractable disorder.
The previous investigation of potential genetic modifiers of HD
has largely relied upon biased candidate gene studies, but none
has identified a locus of genome-wide significance. The findings
have been weak and inconsistent even for the same gene, likely
reflecting a lack of power and statistical stringency, variable
phenotype definition, and population stratification. Indeed, in
our GWAS, none of the previously suggested candidate modi-
fiers achieved p < 1 3 105. However, two previous unbiased
genetic-linkage modifier searches in HD sib pairs from North
America, Europe, and Australia (Li et al., 2003, 2006) or in families
limited to Venezuela (Gaya´n et al., 2008) yielded genome-wide
significant peaks at 6q23-q24 (LOD = 4.05) or at 2p25 (LOD =
4.29), respectively, with trends in the latter at 2q35 (LOD =
3.39), 5p14 (LOD = 3.31), and 5q32 (LOD = 3.14). None of the
most significant association signals and none of the trending
SNPs (p < 13 105) from our European GWA analysis corre-
spond to any of these linkage regions. The lack of overlap be-
tween our GWA and the Venezuela linkage scan could be
explained simply by population differences in the modifier
alleles present. The difference with the other linkage study,
which included subjects expected to be primarily of European522 Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc.ancestry, more likely represents either a diversity of modifier
alleles at the 6q23-q24 locus detectable by linkage but not by
association in this sample or inaccuracy in precisely localizing
the linkage peak, as there is a nearby association signal at
6q23 (top SNP rs6934819, p = 2.83 106). A similar discrepancy
between GWA and linkage results has been seen for risk factors
in some complex disorders (Weiss et al., 2009).
The genome-wide significant loci identified here permit dis-
covery of the specific functional variants responsible for the
modifier effects and the genes through which they act. Both
the chr15 and chr8 loci offer attractive candidates. On chr15,
the presence of two independent genome-wide significant sig-
nals in the same region reflects two functional variants, with
Occam’s razor arguing that these are likely to affect the same
gene. The two strongest locational candidates, FAN1 and
MTMR10, are implicated in functions previously suggested in
studies of HD pathogenesis: structure-specific DNA handling
and inositol-phosphate signaling, respectively. The FAN1
nuclease plays a role in repair of DNA inter-strand cross-links
but not of double-strand breaks (Kratz et al., 2010; Liu et al.,
2010; MacKay et al., 2010) and has recently been identified as
essential for restart of paused replication forks in DNA synthesis
(Chaudhury et al., 2014). MTMR10, although catalytically inac-
tive, is thought, like other suchmyotubularin-related familymem-
bers, to heterodimerize with an active phosphatase subunit to
act on phosphatidylinositol phosphates (Hnia et al., 2012). The
top SNPs for each of the two independent signals are located
upstream of FAN1 and within MTMR10, respectively, although
each is backed by a distinct, extensive set of associated SNPs
spanning both genes. FAN1 and MTMR10 lie within a larger
2 Mb region of copy-number variation (CNV) due to non-allelic
Figure 4. Fourteen Significant Pathways (q < 0.05) from the Main Setscreen Analysis Clustered by Gene Membership
Thickness of line connecting two pathways is proportional to the number of genes shared between them. The size of the node is proportional to the number of
SNPs. The intensity of shading is inversely proportional to the q value; deep shades of red have low q values, and pale shading is close to the 5% threshold.
Pathways were assigned to clusters as follows: For each pair of pathways, an overlap measure K was defined as the number of genes common to both pathways
divided by the number of genes in the smaller pathway. A pathway was assigned to a cluster if the average K between it and the pathways already in the cluster
was greater than 0.4. If it was not possible to assign a pathway to an existing cluster, a new cluster was started. This procedure was carried out recursively, in
descending order of enrichment significance.
See also Tables S3, S4, and S5.homologous recombination of flanking repeats. Both deletion
and duplication of the region have been associated with intellec-
tual disability, epilepsy, and autism, with the former also associ-
ated with schizophrenia. Although no genome-wide significant
GWA signal has been reported in this segment for autism,
schizophrenia, or other psychiatric disorders, it has been sug-
gested that FAN1 may drive neurodevelopmental susceptibility
based upon an increased frequency of rare missense variants
(Ionita-Laza et al., 2014). Analysis of our GWA data using (1)
the number of CNV segments (p = 0.7819), (2) total CNV size
(p = 0.853), and (3) average of CNV segment size (p = 0.5201)
did not support a contribution of CNV to our HDmodifier associ-
ation signals, indicating that more subtle but relatively common
genetic variants are responsible for the HD modifier effect.
Very recent data show that the same 2 Mb segment of 15q13.3
is inverted without change in copy number at low but readily
measurable frequency in the normal population (Antonacci
et al., 2014). It will be interesting to determine whether SNPs
tagging either of the functional effects that we have observed
are present on inversion chromosomes. However, in either
circumstance, the fact that our genome-wide association signals
extend over < 250 kb of the internal region suggests that it will be
possible to use haplotyping and sequence analysis to home in on
the functional variants, which are likely to act via one of these two
genes.
The same strategies can apply to the single functional variant
implicated on chr8, where the association signals extend
over < 250 kb spanning two prime locational candidates,
RRM2B and UBR5. These genes are involved in additional func-tions previously suggested to play a role in HD pathogenesis:
mitochondrial energetics and oxidative stress, and proteostasis.
As a subunit in quiescent cells of the rate-limiting enzyme in new
deoxyribonucleotide triphosphate synthesis (Pontarin et al.,
2011), RRM2B has effects on DNA synthesis and repair (Pontarin
et al., 2012). It also regulates mitochondrial DNA content (Bour-
don et al., 2007) and suppresses activation of the oxidative
stress pathway (Kuo et al., 2012). Proteasome-mediated protein
degradation due to tagging by E3 ubiquitin ligases like UBR5 is
critical to many cellular processes and has been a focus of HD
research due to the intracellular accumulation of misfolded poly-
glutamine fragments of mutant huntingtin (Ortega and Lucas,
2014).
Although we believe it most likely that the modifiers act
through intersection with the biology of HD pathogenesis, it is
formally possible that they act through an independent effect
on motor control in aging and modify HD age at onset additively.
None of the top SNPs on chr15, chr8, or chr3 SNPs has been
associated with any phenotype in previous GWASs, including
analysis of age at onset of Parkinson disease, a movement dis-
order wherein a similar additive effect might be predicted. The
effect sizes of 6 to +1.4 years, determined from CAG repeat
lengths typically associated with a mean onset range of 20 to
60 years, would indicate a substantial effect in mid-life, but it is
conceivable that more detailed phenotyping of normal individ-
uals may reveal HD-independent effects of these loci. Investiga-
tion of other movement disorders might also reveal an influence
of these loci, particularly if the other disorder shares aspects of
pathogenesis with HD.Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc. 523
Table 3. Association of Top Loci with Other Phenotypes
SNP Chr
Age at Onset
of Motor
Signs
Age at Onset
of Cognitive
Signs
Age at Onset
of Psychiatric
Signs
p value p value p value
rs146353869 15 7.0 3 1019 7.6 3 103 2.7 3 107
rs2140734 15 4.7 3 1013 1.1 3 103 4.8 3 103
rs1037699 8 1.2 3 107 8.7 3 104 4.1 3 102
rs144287831 3 5.1 3 107 9.7 3 101 7.6 3 102
See also Figure S2.In HD itself, the effect is substantial, representing 8%–33%
of the typical disease duration and as much as 25%–30% of
the life span prior to diagnosis. This is most evident in the
odds-ratios from extreme dichotomous analysis, which, at 1.8
to 18.1 (Table S2), far exceed those in most disease GWAS
where small additive risk effects are the norm. Although larger
effect sizes may prove to be more frequent in modifier-based
than in risk-based GWAS, they are not a prerequisite for judging
a modifier’s value in directing therapeutic development, as phar-
maceutical interventions have the potential for stronger effects
than naturally occurring human variation on disease-modifying
processes.
Although not quite achieving genome-wide significance, prior
discovery in CAG repeat knockin mouse genetic modifier screen
strongly supports the candidacy of MLH1 at the chr3 locus and
implicates DNA mismatch repair as a process that modifies HD
pathogenesis (Pinto et al., 2013). This proposal receives further
support from our pathway analyses. Genes involved in DNA
mismatch repair pathways were enriched for association with
HD residual age at onset. In humans, inactivation of MLH1 and
other mismatch repair genes, predominantly MSH2, MSH6,
and PMS2, is associated with dinucleotide repeat instability in
certain cancers (Sehgal et al., 2014). By contrast, inactivation
of some mismatch repair genes (Msh2,Msh3, Mlh1,Mlh3) elim-
inates somatic instability of the CAG repeat in Htt CAG knockin
mice, and knock out of Mlh1, and other mismatch repair genes,
also slows the pathogenic process in these precise genetic HD
replicas (Dragileva et al., 2009; Pinto et al., 2013). Given that
Mlh1 and other mismatch repair genes influence CAG instability
in knockin mice, and longer HTT CAG repeat expansions in HD
post-mortem brain are associated with earlier disease onset
(Swami et al., 2009), one would predict that MLH1 modifies
disease onset in patients as a consequence of an effect on
somatic HTT CAG repeat instability. However, although attrac-
tive, this assumption should be tested further. The HD knockin
mouse studies do not a priori rule out the possibility that DNA
repair genes might modify HD pathogenesis via DNA structure-
specific functions unrelated to their activities in enhancing
CAG instability.
The identification of genetic modifier loci that alter the course
of HD prior to disease onset opens an entirely new direction for
development of therapies to prevent the onset of this devastating
disorder. To truly understand the modifier mechanisms, addi-
tional work is needed to identify the functional DNA variant and
gene(s) responsible for mediating the modifier effect at each524 Cell 162, 516–526, July 30, 2015 ª2015 Elsevier Inc.locus. Follow-up to our initial lead is enabled by the ongoing
collection of additional well-phenotyped DNA samples from
large HD natural history studies and clinical trials. Adding sam-
ples will power genome-wide association to detect many more
modifiers and to potentially reveal additional pathways by which
HD pathogenesis can be altered. Similarly, the analysis of non-
European subjects offers the potential for identifying additional
alleles at these modifier loci and/or additional loci specific to
certain populations. Applying this approach to other HD pheno-
types, both before and after disease onset, may, as our findings
already suggest, reveal modifiers that distinguish different dis-
ease domains. All of these pursuits will accelerate the ability to
translate natural disease modification by genetic factors into
directed disease modification by human intervention.
The genetic modifiers defined here have already identified one
pathway, DNA handling, whose manipulation may provide ther-
apeutic benefit in HD. Investigation of the chr15 and chr8 loci
is likely to provide additional targets. Even before thesemodified
loci are fully understood and additional modifiers are found, our
findings will have a profound impact in a number of areas. As a
proof-of-principle, they will spur pursuit of this genetic modifier
strategy in other Mendelian disorders with quantitative or
discrete qualitative differences in phenotype. In basic research,
they will open paths into understanding the pathogenic process
in HD by providing human-relevant tools with which to perturb it.
In clinical research, they will provide the basis for genotype-
phenotype studies to more fully explore the phenotypic corre-
lates of each mechanism of disease modification. For clinical
trials, stratification of the patient population and/or quantitation
of the outcomes in a manner that takes into account the effects
of patient genotype at these loci will permit smaller, less costly
trials with greater power to detect therapeutic benefit. Finally,
for HD families, our findings present the hope of novel in-human
validated targets to accelerate development of treatments and
represent a validation of their active and willing participation in
HD studies that have made such large-scale investigations
possible.EXPERIMENTAL PROCEDURES
Subjects and Residual Phenotype
Patient consents and the overall study were reviewed and approved by the
Partners HealthCare Institutional Review Board. The sources of subjects are
described in Supplemental Experimental Procedures. We used age at onset
of motor signs and CAG repeat length to derive residual age at onset of motor
signs, which we used as the primary phenotype for the GWAS to identify ge-
netic modifiers of HD. In order to subtract the effects of CAG repeats from
the age at onset of motor signs, we used a phenotype model previously devel-
oped through stringent data analysis (Lee et al., 2012b). Thismodel relates nat-
ural log-transformed age at onset of motor signs to CAG repeat length using
only normally distributed data points. In the current study, the previously es-
tablished phenotype model (intercept, 7.01; slope, 0.073) was interrogated
with CAG repeat lengths of study subjects of CAG lengths 40–55 to obtain in-
dividual predicted age at onset of motor signs, which we transformed into nat-
ural scale for calculating the difference between predicted and actual age at
motor onset, i.e., the residual age at motor onset. For example, a residual
age at onset of 10 for a HD subject indicates that the individual developed
motor signs 10 years earlier than expected from his or her CAG repeat length.
The distribution of residual age at onset of motor signs of study subjects was
very similar to a theoretical normal distribution.
GWA Analysis
Quantitative GWA analysis used mixed-effect linear regression analysis,
modeling residual age at motor onset as a function of minor allele count of a
SNP and gender and ancestry covariates. For extreme dichotomous analysis,
we directly compared genome-wide SNP allele frequencies of those individ-
ualswhose residual age atmotor onsetwas among the 20%extremes, respec-
tively representing earlier and later than expected onset. As no prior statistical
model was available for other onset phenotypes, for these we modeled log-
transformed age at onset of cognitive signs or psychiatric signs as a function
ofCAG repeat length,minor allele count of a test SNP, andgender and ancestry
covariates in a linear regression analysis framework to determine the extent to
which the test SNP explains the amount of variance in phenotype.
Pathway Analysis
The primary pathway analysis was performed using Setscreen (Moskvina
et al., 2011), with secondary analyses using ALIGATOR (Holmans et al.,
2009), and GSEA (Wang et al., 2007) as described in Supplemental Experi-
mental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, five tables, and a full list of GeM-HD Consortium Members and
can be found with this article online at http://dx.doi.org/10.1016/j.cell.2015.
07.003.
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